Terms: = Prostate cancer AND ACVR2A, ACVR2, 92, ENSG00000121989, ACTRII, P27037 AND Treatment
1620 results:
1. Value of next generation sequencing (NGS) testing in advanced cancer patients.
Ortendahl JD; Cuyun Carter G; Thakkar SG; Bognar K; Hall DW; Abdou Y
J Med Econ; 2024; 27(1):519-530. PubMed ID: 38466204
[TBL] [Abstract] [Full Text] [Related]
2. Diagnostic value of
Guo S; Zhou C; Zhang Y; Wang D; Niu T; Zhou F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 48(12):1812-1819. PubMed ID: 38448374
[TBL] [Abstract] [Full Text] [Related]
3. Partial gland ablation with high intensity focal ultrasound impact on genito-urinary function and quality of life: our initial experience.
Fugaru I; Bouhadana D; Marcq G; Moryousef J; Rompré-Brodeur A; Meng A; Loutochin O; Loutochin G; Anidjar M; Bladou F; Sanchez-Salas R
Can J Urol; 2024 Feb; 31(1):11784-11792. PubMed ID: 38401258
[TBL] [Abstract] [Full Text] [Related]
4. Development of CD46 targeted alpha theranostics in prostate cancer using
Bobba KN; Bidkar AP; Wadhwa A; Meher N; Drona S; Sorlin AM; Bidlingmaier S; Zhang L; Wilson DM; Chan E; Greenland NY; Aggarwal R; VanBrocklin HF; He J; Chou J; Seo Y; Liu B; Flavell RR
Theranostics; 2024; 14(4):1344-1360. PubMed ID: 38389832
[No Abstract] [Full Text] [Related]
5. Systemic interrogation of immune-oncology-related proteins in patients with locally advanced prostate cancer undergoing androgen deprivation and intensity-modulated radiotherapy.
Guldvik IJ; Ramberg H; Kristensen G; Røder A; Mills IG; Lilleby W; Taskén KA
World J Urol; 2024 Feb; 42(1):95. PubMed ID: 38386171
[TBL] [Abstract] [Full Text] [Related]
6. Medication-based Comorbidity Measures and prostate cancer treatment Selection.
Tiruye T; O'Callaghan M; FitzGerald LM; Moretti K; Jay A; Higgs B; Kichenadasse G; Caughey G; Roder D; Beckmann K
Clin Genitourin Cancer; 2024 Apr; 22(2):599-609.e2. PubMed ID: 38369388
[TBL] [Abstract] [Full Text] [Related]
7. Revolutionizing localized prostate cancer treatment: Stereotactic radiotherapy "Moroccan experience".
Naim A; Lahlou Z; Kaanouch O; Heddat A; Mansouri S
Arch Ital Urol Androl; 2024 Feb; 96(1):12104. PubMed ID: 38363238
[TBL] [Abstract] [Full Text] [Related]
8. Salvage vesiculectomy for local prostate cancer recurrence: surgical technique and early post-operative outcomes.
Giesen A; Van den Broeck T; Develtere D; Raskin Y; Wymer K; Eden C; Claessens M; Hente R; Rans K; Berghen C; De Meerleer G; Langley S; Karnes RJ; Heidenreich A; Pfister D; Joniau S
World J Urol; 2024 Feb; 42(1):81. PubMed ID: 38358521
[TBL] [Abstract] [Full Text] [Related]
9. Secondary bladder and colorectal cancer after treatments for prostate cancer: A population based study.
Bárcena PGQ; Aprikian AG; Dragomir A
Cancer Med; 2024 Feb; 13(3):e6922. PubMed ID: 38351647
[TBL] [Abstract] [Full Text] [Related]
10. Comparing the use of aggressive end-of life care among frail and non-frail patients with cancer using a claims-based frailty index.
Sachdev R; Shearn-Nance G; Vu L; Bensken WP; Douglas SL; Koroukian SM; Rose J
J Geriatr Oncol; 2024 Mar; 15(2):101706. PubMed ID: 38320468
[TBL] [Abstract] [Full Text] [Related]
11. Quantified treatment effect at the individual level is more indicative for personalized radical prostatectomy recommendation: implications for prostate cancer treatment using deep learning.
Pan H; Wang J; Shi W; Xu Z; Zhu E
J Cancer Res Clin Oncol; 2024 Feb; 150(2):67. PubMed ID: 38302801
[TBL] [Abstract] [Full Text] [Related]
12. Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells.
Gurrea-Rubio M; Wu Q; Amin MA; Tsou PS; Campbell PL; Amarista CI; Ikari Y; Brodie WD; Mattichak MN; Muraoka S; Randon PM; Lind ME; Ruth JH; Mao-Draayer Y; Ding S; Shen X; Cooney LA; Lin F; Fox DA
Cancer Immunol Immunother; 2024 Jan; 73(2):34. PubMed ID: 38280067
[TBL] [Abstract] [Full Text] [Related]
13. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
[TBL] [Abstract] [Full Text] [Related]
14. Automatic Detection of Distant Metastasis Mentions in Radiology Reports in Spanish.
Ahumada R; Dunstan J; Rojas M; Peñafiel S; Paredes I; Báez P
JCO Clin Cancer Inform; 2024 Jan; 8():e2300130. PubMed ID: 38194615
[TBL] [Abstract] [Full Text] [Related]
15. Prevalence of germline BRCA1/2 pathogenic variants in Japanese patients treated with castration-resistant prostate cancer and efficacy of CRPC treatment in real-world clinical practice.
Maekawa S; Takata R; Sekiguchi K; Kagabu M; Toyoshima M; Tamada S; Takahashi K; Ikarashi D; Matsuura T; Kato R; Kato Y; Kanehira M; Sugimura J; Abe T; Baba T; Obara W
Jpn J Clin Oncol; 2024 Apr; 54(4):489-497. PubMed ID: 38157885
[TBL] [Abstract] [Full Text] [Related]
16. Radiological imaging protection: a study on imaging dose used while planning computed tomography for external radiotherapy in Japan.
Kito S; Suda Y; Tanabe S; Takizawa T; Nagahata T; Tohyama N; Okamoto H; Kodama T; Fujita Y; Miyashita H; Shinoda K; Kurooka M; Shimizu H; Ohno T; Sakamoto M
J Radiat Res; 2024 Mar; 65(2):159-167. PubMed ID: 38151953
[TBL] [Abstract] [Full Text] [Related]
17. prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial.
Bhasin S; Travison TG; Pencina KM; O'Leary M; Cunningham GR; Lincoff AM; Nissen SE; Lucia MS; Preston MA; Khera M; Khan N; Snabes MC; Li X; Tangen CM; Buhr KA; Thompson IM
JAMA Netw Open; 2023 Dec; 6(12):e2348692. PubMed ID: 38150256
[TBL] [Abstract] [Full Text] [Related]
18. FDA Approval Summary: Olaparib in Combination With Abiraterone for treatment of Patients With
Fallah J; Xu J; Weinstock C; Brave MH; Bloomquist E; Fiero MH; Schaefer T; Pathak A; Abukhdeir A; Bhatnagar V; Chiu HJ; Ricks T; John C; Hamed S; Lee C; Pierce WF; Kalavar S; Philip R; Tang S; Amiri-Kordestani L; Pazdur R; Kluetz PG; Suzman D
J Clin Oncol; 2024 Feb; 42(5):605-613. PubMed ID: 38127780
[TBL] [Abstract] [Full Text] [Related]
19. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.
Grande E; Arranz JÁ; De Santis M; Bamias A; Kikuchi E; Del Muro XG; Park SH; De Giorgi U; Alekseev B; Mencinger M; Izumi K; Schutz FA; Puente J; Li JR; O'Donnell PH; Kalebasty AR; Ye D; Mariathasan S; Bene-Tchaleu F; Bernhard S; Lee C; Davis ID; Galsky MD
Lancet Oncol; 2024 Jan; 25(1):29-45. PubMed ID: 38101433
[TBL] [Abstract] [Full Text] [Related]
20. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.
Bamias A; Davis ID; Galsky MD; Arranz JÁ; Kikuchi E; Grande E; Del Muro XG; Park SH; De Giorgi U; Alekseev B; Mencinger M; Izumi K; Schutz FA; Puente J; Li JR; Panni S; Gumus M; Özgüroğlu M; Mariathasan S; Poloz Y; Bene-Tchaleu F; Lee C; Bernhard S; De Santis M
Lancet Oncol; 2024 Jan; 25(1):46-61. PubMed ID: 38101431
[TBL] [Abstract] [Full Text] [Related]
[Next]
